Maryland HB 755: Public Health - Gabapentin - Monitoring by Prescription Drug Monitoring Program and Report

Status: Unfavorable Report by Health and Government Operations; Withdrawn (as of 2019-04-04)

State: Maryland · Session: 2019 · Bill: HB 755

Subjects: Public Health, Controlled Dangerous Substances, Drugs, Examinations, Health, Health, Department of, Medical Treatments, Reports

Sponsors: Kipke

View Maryland HB 755 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.